In the present study, a series of 3-benzylquinazolin-4(3H)-ones were synthesized and characterized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with 60 mM KCl. The SAR of target compounds was discussed preliminarily. Among these compounds, 2a and 2c displayed potent vasodilatation action and could compete significantly the
在本研究中,合成并表征了一系列3-苄基喹唑啉-4(3 H)-one 。通过钢丝肌电图仪评估其对离体大鼠肠系膜动脉环诱导的60 mM KCl收缩的血管舒张作用。初步讨论了目标化合物的SAR。在这些化合物中,2a和2c表现出有效的血管舒张作用,并且可以与苯肾上腺素显着竞争大鼠肠系膜动脉环诱导的收缩。通过口服给药,进一步测试了化合物2a和2c在SHR中的抗高血压作用。结果表明2a和2c可以显着降低舒张压和收缩压。此外,2c以剂量依赖性方式显示抗高血压作用,并且在4.0 mg / kg的剂量下可维持6 h的作用。这些发现表明标题化合物是新型血管舒张剂,代表了一系列新的有希望的降压药。